Dyadic Launches Recombinant Human Albumin with Proliant, Targeting Animal-Free Life Science Markets
Event summary
- Dyadic and Proliant launched AlbuFree™ DX, a recombinant human albumin (rHA) product, on February 17, 2026.
- Dyadic’s fungal expression technology enables animal-free, scalable production for life science applications.
- Proliant will distribute the product globally, with further expansion planned for cell culture markets later in 2026.
- Dyadic will receive a share of profits from Proliant’s commercial sales of the product.
The big picture
The launch validates Dyadic’s strategy of focusing on recombinant proteins with clear commercial pathways. It also underscores the growing industry shift toward animal-free, scalable solutions in life science applications. Proliant’s established distribution network provides a strong foundation for market penetration, while Dyadic’s technology positions it for further expansion in high-demand sectors.
What we're watching
- Market Adoption
- How quickly AlbuFree™ DX gains traction in cell culture and life science markets, given rising demand for animal-free inputs.
- Revenue Growth
- Whether Dyadic can sustain recurring revenue streams from this and future recombinant protein partnerships.
- Technological Scalability
- The pace at which Dyadic’s fungal expression platform can be adapted for additional high-value recombinant proteins.
Related topics